These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7474898)

  • 1. Heterozygotes for plasmalemmal carnitine transporter defect are at increased risk for valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts.
    Tein I; DiMauro S; Xie ZW; De Vivo DC
    J Inherit Metab Dis; 1995; 18(3):313-22. PubMed ID: 7474898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproic acid impairs carnitine uptake in cultured human skin fibroblasts. An in vitro model for the pathogenesis of valproic acid-associated carnitine deficiency.
    Tein I; DiMauro S; Xie ZW; De Vivo DC
    Pediatr Res; 1993 Sep; 34(3):281-7. PubMed ID: 8134167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts.
    Tein I; Xie ZW
    Biochem Biophys Res Commun; 1994 Oct; 204(2):753-8. PubMed ID: 7980539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the human plasmalemmal carnitine transporter in cultured skin fibroblasts.
    Tein I; Bukovac SW; Xie ZW
    Arch Biochem Biophys; 1996 May; 329(2):145-55. PubMed ID: 8638946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carnitine transport: pathophysiology and metabolism of known molecular defects.
    Tein I
    J Inherit Metab Dis; 2003; 26(2-3):147-69. PubMed ID: 12889657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy.
    Tein I; De Vivo DC; Bierman F; Pulver P; De Meirleir LJ; Cvitanovic-Sojat L; Pagon RA; Bertini E; Dionisi-Vici C; Servidei S
    Pediatr Res; 1990 Sep; 28(3):247-55. PubMed ID: 2235122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin fibroblast carnitine uptake in secondary carnitine deficiency disorders.
    Tein I; De Vivo DC; Ranucci D; DiMauro S
    J Inherit Metab Dis; 1993; 16(1):135-46. PubMed ID: 8387612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carnitine uptake defect: frameshift mutations in the human plasmalemmal carnitine transporter gene.
    Lamhonwah AM; Tein I
    Biochem Biophys Res Commun; 1998 Nov; 252(2):396-401. PubMed ID: 9826541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GFP-Human high-affinity carnitine transporter OCTN2 protein: subcellular localization and functional restoration of carnitine uptake in mutant cell lines with the carnitine transporter defect.
    Lamhonwah AM; Tein I
    Biochem Biophys Res Commun; 1999 Nov; 264(3):909-14. PubMed ID: 10544029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of acute valproate administration on carnitine metabolism in mouse serum and tissues.
    Rozas I; Camiña MF; Paz JM; Alonso C; Castro-Gago M; Rodriguez-Segade S
    Biochem Pharmacol; 1990 Jan; 39(1):181-5. PubMed ID: 2105093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of recognition and interaction of carnitine transporter in the decrease of L-carnitine concentration induced by pivalic acid and valproic acid.
    Okamura N; Ohnishi S; Shimaoka H; Norikura R; Hasegawa H
    Pharm Res; 2006 Aug; 23(8):1729-35. PubMed ID: 16826461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between anticonvulsants and human placental carnitine transporter.
    Wu SP; Shyu MK; Liou HH; Gau CS; Lin CJ
    Epilepsia; 2004 Mar; 45(3):204-10. PubMed ID: 15009220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in the carnitine metabolism in epileptic children treated with valproic acid.
    Chung S; Choi J; Hyun T; Rha Y; Bae C
    J Korean Med Sci; 1997 Dec; 12(6):553-8. PubMed ID: 9443096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
    Goto S; Seo T; Hagiwara T; Ueda K; Yamauchi T; Nagata S; Ando Y; Ishitsu T; Nakagawa K
    J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carnitine metabolism in valproate-treated rats: the effect of L-carnitine supplementation.
    Nishida N; Sugimoto T; Araki A; Woo M; Sakane Y; Kobayashi Y
    Pediatr Res; 1987 Nov; 22(5):500-3. PubMed ID: 3120144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene-dose effect on carnitine transport activity in embryonic fibroblasts of JVS mice as a model of human carnitine transporter deficiency.
    Hashimoto N; Suzuki F; Tamai I; Nikaido H; Kuwajima M; Hayakawa J; Tsuji A
    Biochem Pharmacol; 1998 May; 55(10):1729-32. PubMed ID: 9634010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of carnitine biosynthesis by valproic acid in rats--the biochemical mechanism of inhibition.
    Farkas V; Bock I; Cseko J; Sandor A
    Biochem Pharmacol; 1996 Nov; 52(9):1429-33. PubMed ID: 8937454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on functional sites of organic cation/carnitine transporter OCTN2 (SLC22A5) using a Ser467Cys mutant protein.
    Ohashi R; Tamai I; Inano A; Katsura M; Sai Y; Nezu J; Tsuji A
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1286-94. PubMed ID: 12183691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores.
    Knapp AC; Todesco L; Beier K; Terracciano L; Sägesser H; Reichen J; Krähenbühl S
    J Pharmacol Exp Ther; 2008 Feb; 324(2):568-75. PubMed ID: 17986647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.